Zobrazeno 1 - 10
of 39
pro vyhledávání: '"RONALD L. BRAZG"'
Autor:
Satish K, Garg, George, Grunberger, Ruth, Weinstock, Margaret L, Lawson, Irl B, Hirsch, Linda A, DiMeglio, Rodica, Pop-Busui, Athena, Philis-Tsimikas, Mark, Kipnes, David R, Liljenquist, Ronald L, Brazg, Yogish C, Kudva, Bruce A, Buckingham, Janet B, McGill, Anders L, Carlson, Amy B, Criego, Mark P, Christiansen, Kevin B, Kaiserman, Kurt J, Griffin, Greg P, Forlenza, Bruce W, Bode, Robert H, Slover, Ashleigh, Keiter, Chenxiao, Ling, Briggitte, Marinos, Toni L, Cordero, John, Shin, Scott W, Lee, Andrew S, Rhinehart, Robert A, Vigersky, Mary, Jane Clifton
Publikováno v:
Diabetes Technology & Therapeutics. 25:1-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0713dbe8c9a3f158f7243c139fea68
https://doi.org/10.1089/dia.2022.0421
https://doi.org/10.1089/dia.2022.0421
Autor:
ROBERT A. VIGERSKY, BRUCE W. BODE, RONALD L. BRAZG, BRUCE A. BUCKINGHAM, ANDERS L. CARLSON, KEVIN B. KAISERMAN, MARK KIPNES, DAVID R. LILJENQUIST, ATHENA PHILIS-TSIMIKAS, CATHERINE PIHOKER, RODICA POP-BUSUI, JOHN REED, JENNIFER SHERR, DOROTHY I. SHULMAN, ROBERT H. SLOVER, JAMES THRASHER, XIAOXIAO CHEN, MARGARET LIU, TONI L. CORDERO, MELISSA VELLA, ANDREW S. RHINEHART, JOHN SHIN
Publikováno v:
Diabetes. 71
Background: Safety and effectiveness outcomes of individuals using the MiniMed™ 780G system with the no-calibration Guardian™ 4 sensor during the first three months of use were analyzed. Methods: Participants (N=176, aged 7-75 years) with T1D use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ad1ab3c86af12c2910313a11fd45e99
https://doi.org/10.2337/db22-100-lb
https://doi.org/10.2337/db22-100-lb
Autor:
SHRIDHARA A. KARINKA, RONALD L. BRAZG, KRISTIN N. CASTORINO, DAVID R. LILJENQUIST, MARK KIPNES, HANQING LIU
Publikováno v:
Diabetes. 71
FreeStyle Libre 3 is the next generation FreeStyle Libre system with the same sensor tail but an on-body component that is about 70% smaller than Libre 2. We evaluated the accuracy of the FreeStyle Libre 3 system in people with diabetes ages 4 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::356b7dcd34a08c4ae73db3043edae915
https://doi.org/10.2337/db22-76-lb
https://doi.org/10.2337/db22-76-lb
Autor:
Mark P. Christiansen, Timothy S. Bailey, Anna R Chang, David R. Liljenquist, Katherine S. Tweden, Francine R. Kaufman, Bruce W. Bode, Ronald L. Brazg, Andrew Dehennis, Halis Kaan Akturk, Satish K. Garg, Douglas S Denham
Publikováno v:
Diabetes Technology & Therapeutics
Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c7c7812c5e776be19b3d74b730237ba
https://pubmed.ncbi.nlm.nih.gov/34515521
https://pubmed.ncbi.nlm.nih.gov/34515521
Autor:
David M Shearer, Vanita R. Aroda, Brian L. Levy, Ramachandra G. Naik, Timothy S. Bailey, Julio Rosenstock, Pierre Serusclat, Mary L. Johnson, Davida F. Kruger, David C. Klonoff, Shenaz Ramtoola, Richard M. Bergenstal, Juan P. Frias, Ronald L. Brazg, Mark Peyrot, Darlene M. Dreon, Ruth S. Weinstock, Vivien Zraick
Publikováno v:
Diabetes Technology & Therapeutics
Background: Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with type 2 diabetes, inadequa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9421082868db4dbdf2c5be097d61aced
http://europepmc.org/articles/PMC6532545
http://europepmc.org/articles/PMC6532545
Autor:
Timothy S. Bailey, Leslie J. Klaff, Katherine S. Tweden, Ronald L. Brazg, Mark P. Christiansen, Grace Carlson
Publikováno v:
Diabetes Technology & Therapeutics
Background: A prior study (PRECISE II) demonstrated that an implantable continuous glucose monitoring (CGM) system (Eversense® CGM System) provided accurate glucose readings through the 90-day sensor life with a favorable safety profile in participa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8190da4a33644a550d97d7aaf476ca
https://doi.org/10.1089/dia.2019.0020
https://doi.org/10.1089/dia.2019.0020
Autor:
Gina Zhang, Barry Horowitz, Ronald L. Brazg, Anuj Bhargava, Satish K. Garg, Yogish C. Kudva, Suiying Huang, Robert Vigersky, Arvind Cavale, George Grunberger, Timothy S. Bailey, Sarnath Chattaraj, Bruce A. Buckingham, John Shin, Vivian Chen, Kevin B Kaiserman, James Thrasher
Publikováno v:
Diabetes. 70
Objective: Most insulin infusion sets (ISs) are labeled for 2- or 3-days use. The Medtronic EWIS is designed to increase wear time up to 7 days. This study reports on EWIS survival and performance during the pivotal trial (ClinicalTrials.gov: NCT0411
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d326dd40f23fa21e724e152827fad1c
https://doi.org/10.2337/db21-100-lb
https://doi.org/10.2337/db21-100-lb
Autor:
David R. Liljenquist, Timothy S. Bailey, Francine R. Kaufman, Mark P. Christiansen, Satish K. Garg, Halis Kaan Akturk, Douglas S Denham, Andrew Dehennis, Bruce W. Bode, Katherine S. Tweden, Ronald L. Brazg, Anna Chang
Publikováno v:
Diabetes. 70
Background: The prospective, multi-center PROMISE study evaluated the safety and accuracy of the next generation Eversense CGM System for up to 180 days in 181 adults with diabetes at 8 US clinical sites. Methods: Accuracy was evaluated by comparing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d117607bfc477e210c9d74186a1179ef
https://doi.org/10.2337/db21-149-or
https://doi.org/10.2337/db21-149-or
Autor:
Vivian Chen, Kevin B Kaiserman, James Thrasher, Anuj Bhargava, Suiying Huang, Barry Horowitz, Bruce A. Buckingham, John Shin, George Grunberger, Gina Zhang, Satish K. Garg, Ronald L. Brazg, Timothy S. Bailey, Arvind Cavale, Robert Vigersky, Sarnath Chattaraj, Yogish C. Kudva
Publikováno v:
Diabetes. 70
Objective: Most insulin infusion sets (ISs) are labeled for 2- or 3-days use. The Medtronic EWIS is designed to increase wear time up to 7 days, and demonstrated a 74.8% survival rate (77.8%, excluding inadvertent early removal) in the pivotal trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1782e8527536b4b5d263d12dc549e2d6
https://doi.org/10.2337/db21-101-lb
https://doi.org/10.2337/db21-101-lb
Autor:
David R Liljenquist, Kristin Castorino, Ronald L. Brazg, Gregory P. Forlenza, Hanqing Liu, Mark P. Christiansen, Mark Kipnes, Timothy L. Bailey, Shridhara Alva, Erwin S. Budiman
Publikováno v:
J Diabetes Sci Technol
Background: In this study, we evaluated the analytical performance of the second-generation factory-calibrated FreeStyle Libre Flash Glucose Monitoring (FreeStyle Libre 2) System compared to plasma venous blood glucose reference, Yellow Springs Instr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc943859190787dbebbf9d920f2c3ed2
https://europepmc.org/articles/PMC8875061/
https://europepmc.org/articles/PMC8875061/
